Cellebrite Thomas Hogan Sells 103K Shares: Investor Outlook
Cellebrite's CEO moved a sizable stake, selling 103,000 shares for about $1.6 million. This article breaks down what ...
Benchmarks provide objective yardsticks to assess results, set expectations, and keep portfolios aligned with objectives.
20,321 articlesCellebrite's CEO moved a sizable stake, selling 103,000 shares for about $1.6 million. This article breaks down what ...
July brought a surprising bounce in the stock market as a major theater chain beat earnings expectations and drew att...
The monthly nonfarm payrolls report is a big market event, but it can mislead if you lean on it without guarding agai...
Grail stock showed a notable bounce after several tough sessions tied to trial updates. This piece breaks down what’s...
A major fund reported a sizeable exit from an offshore energy stake, triggering a review of how investors manage risk...
When a celebrity challenges political messaging, it’s more than headlines. It’s a reminder to take control of your mo...
Mid-term rentals are moving into the spotlight for investors seeking steady cash flow with manageable risk. This guid...
As major retailers push Beyond Meat into the frozen aisle, investors debate the stock's trajectory. This guide breaks...
Chinese automakers are shifting from passenger cars to commercial fleets, challenging Ford's margins and strategy. Th...
If you’re exploring how to invest in ETFs 2026, you’re not alone. This guide breaks down practical, actionable steps ...
Nvidia is expanding beyond chips by taking stakes in fellow AI players. This strategic move could quietly power growt...
Investors rotated into defensive names, helping Molina Healthcare stock cruised to near-a-10% weekly gain. Learn what...